^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) + volasertib (NBL-001) (PLK1 inhibitor) + BI2536 (PLK1 inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P71.03 - A New Combination Therapy for FGFR1-Amplified Lung Cancer
Published date:
08/18/2021
Excerpt:
Specifically, in H1703, H520 cell lines xenografts and a PDX model of FGFR1-amplified lung cancer cells, the combination treatment (AZD4547 plus BI2536/BI6727) led to significantly greater inhibition of tumor growth than single agents, while there are no apparent toxicities (monitored by mouse body weights) associated with the drug combination.
